MNMD | Mind Medicine (MindMed) Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	7.05 - 7.48
52 Week Range	3.50 - 12.22
Beta	2.61
Implied Volatility	95.37%
IV Rank	34.06%
Day's Volume	1,326,959
Average Volume	1,420,911
Shares Outstanding	73,331,690
Market Cap	526,521,534
Sector	Healthcare
Industry	Biotechnology
IPO Date	2016-11-15

Valuation
Profitability
Growth
Health
P/E Ratio	-4.20
Forward P/E Ratio	-1.58
EPS	-1.71
1YR Price Target	21.50
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	57
Country	Canada
Website	MNMD

Mind Medicine Inc is a psychedelic medicine biotech company that discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of treatments based on psychedelic substances including Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative, 18-MC. The firm is having an approach towards developing the next generation of psychedelic inspired medicines and therapies.

MNMD's peers: ATAI, CYBN, SEEL, GHRS, AWKNF, FRLN, BPTH, VCNX, ELYM, OPT, MOLN, EWTX, ITOS, CKPT, MBIO, RVPH, FBIOP, KOD

*Chart delayed

Analyzing fundamentals for MNMD we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is passable. For more detailed analysis please see MNMD Fundamentals page.

Watching at MNMD technicals we can see that long-term trend is bearish, while middle-term trend is bullish, but short-term trend is bearish. More technicals details can be found on MNMD Technicals page.